Spotlight On 3 ASX Penny Stocks With Market Caps Over A$30M

Australian shares are poised for a modest gain, buoyed by Wall Street's resilience despite challenges in the tech and semiconductor sectors. Amidst these broader market movements, penny stocks continue to capture investor interest due to their potential for growth at accessible price points. While the term "penny stocks" might seem outdated, these smaller or newer companies can offer unique opportunities when backed by solid financials and fundamentals.

We're going to check out a few of the best picks from our screener tool.

AMA Group (ASX:AMA)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: AMA Group Limited operates a collision repair business across Australia and New Zealand, with a market capitalization of A$214.26 million.

Operations: The company's revenue segments include Ama Collision with A$378.43 million, Capital Smart generating A$498.13 million, ACM Parts contributing A$99.53 million, Specialist Businesses at A$61.90 million, and Wales with A$79.08 million in revenue.

Market Cap: A$214.26M

AMA Group Limited, with a market cap of A$214.26 million, is currently unprofitable but shows promise with an 83.84% forecasted annual earnings growth. Despite its negative return on equity and inexperienced management team, the company has reduced losses by 38.1% annually over five years and maintains a satisfactory net debt to equity ratio of 8.5%. The firm trades at good value compared to peers and industry standards, supported by a sufficient cash runway exceeding three years even as free cash flow declines slightly. Recently, AMA announced a share buyback program for up to 9.93% of its capital till May 2027.

• Navigate through the intricacies of AMA Group with our comprehensive balance sheet health report here.
• Examine AMA Group's earnings growth report to understand how analysts expect it to perform.

Nova Eye Medical (ASX:EYE)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Nova Eye Medical Limited is an Australian company that designs, develops, manufactures, markets, and sells surgical devices for glaucoma treatment across various regions including Australia, the United States, Europe, and the Asia Pacific with a market cap of A$38.45 million.

Operations: The company's revenue primarily comes from its Glaucoma Surgical Devices segment, which generated A$32.95 million.

Market Cap: A$38.45M

Nova Eye Medical Limited, with a market cap of A$38.45 million, recently upgraded its sales guidance for fiscal year 2026, reflecting strong performance in the U.S. market where it achieved positive EBITDA from operations. Despite being unprofitable and having a negative return on equity of -44.43%, the company is debt-free and trades at good value relative to peers. It has less than a year of cash runway but covers both short-term (A$5.7M) and long-term liabilities (A$2.1M) with its assets (A$10.6M). The management and board are experienced, averaging tenures of seven and eight years respectively.

• Unlock comprehensive insights into our analysis of Nova Eye Medical stock in this financial health report.
• Learn about Nova Eye Medical's future growth trajectory here.

WT Financial Group (ASX:WTL)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: WT Financial Group Limited offers a variety of financial services and has a market cap of A$54.75 million.

Operations: The company's revenue is primarily derived from B2B Services, generating A$29.70 million, with an additional A$1.30 million coming from B2C Services.

Market Cap: A$54.75M

WT Financial Group Limited, with a market cap of A$54.75 million, is trading 33.7% below its estimated fair value, presenting potential value for investors. The company has shown significant improvement in profitability, with net profit margins rising to 15.8% from -8.7% last year and earnings growing by 29.9%. Its financial stability is underscored by short-term assets exceeding both short and long-term liabilities and debt levels being well-covered by operating cash flow. Despite an unstable dividend track record, the board plans to increase dividends to 1 cent annually. The management team and board are experienced, averaging tenures of over three years.

• Take a closer look at WT Financial Group's potential here in our financial health report.
• Gain insights into WT Financial Group's historical outcomes by reviewing our past performance report.

Key Takeaways

• Click here to access our complete index of 409 ASX Penny Stocks.
• Searching for a Fresh Perspective? Uncover 26 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com